# An observational study on treatment regimens and effectiveness for psoriasis in real-world settings among 407 patients in Southeast China

## TL;DR

A study in China found that new psoriasis treatments work less well in real-world settings than in clinical trials, especially for patients who have been treated before.

## Contribution

The study provides real-world evidence on psoriasis treatment effectiveness and identifies disparities compared to clinical trial outcomes.

## Key findings

- First-time diagnosed patients had higher treatment response rates (76.1%) compared to previously diagnosed patients (62.6%).
- Previously treated patients showed reduced treatment response, highlighting unmet needs in psoriasis management.
- Combination and rotational treatment strategies may improve outcomes for non-responsive patients.

## Abstract

While new targeted therapies have advanced psoriasis treatment, real-world data on comparative effectiveness is lacking. This study analyzed treatment regimens and response in an observational cohort, examining potential disparities between clinical trials and routine practice.

Data from the Psoriasis Standardized Diagnosis and Treatment Center registry were analyzed. Patients with ≥1 follow-up were included. Treatment response was assessed using PASI 50/90 criteria. Factors associated with response were analyzed.

407 patients were included (46 first-time diagnosed, 361 previously diagnosed). A higher proportion of first-time diagnosed patients achieved treatment response than previously diagnosed (76.1% vs. 62.6%). Multivariable analysis identified factors associated with reduced response in previously treated patients.

This real-world study found lower treatment response rates compared to clinical trials, especially in previously treated patients. Disparities highlight remaining unmet needs for psoriasis management. Combination and rotational strategies may improve outcomes in patients unresponsive to available therapies. Ongoing research on novel targets and pathways is warranted to address treatment gaps.